Biocon Biologics to Acquire Viatris' (VTRS) Biosimilars Assets for up to $3.335 billion in Stock and Cash

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. MRNA
7. CSX
8. SPCX
9. WDC
10. QGEN

Go back to Biocon Biologics to Acquire Viatris' (VTRS) Biosimilars Assets for up to $3.335 billion in Stock and Cash

Viatris (VTRS) PT Lowered to $19 at BMO Capital

March 1, 2022 7:16 AM EST

BMO Capital analyst Gary Nachman lowered the price target on Viatris (NASDAQ: VTRS) to $19.00 (from $23.00) while maintaining an Outperform rating.

The analyst commented, "4Q was in-line, but 2022 guidance was light (though FX is factor, guidance seems conservative). Bigger focus taking stock down was Biocon... More

Viatris (VTRS) PT Lowered to $10 at Cowen

February 28, 2022 12:16 PM EST

Cowen analyst Ken Cacciatore lowered the price target on Viatris (NASDAQ: VTRS) to $10.00 (from $15.00) while maintaining a Market Perform rating following weak Q4 results and guidance, and plans to divest some franchises.

The analyst commented, "Following another weak result and 2022 guidance that... More